Drug intelligence / Profile preview

αFAP-PE38

Development stage
Preclinical
Modality
Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

αFAP-PE38 is a recombinant immunotoxin composed of variable regions of a monoclonal antibody targeting fibroblast activation protein (FAP), fused to a truncated form of Pseudomonas exotoxin A (PE38). It binds specifically and with high affinity to FAP, a protein preferentially expressed on tumor-associated stromal fibroblasts in a variety of epithelial cancers. Upon binding FAP, αFAP-PE38 is internalized and delivers the PE38 toxin to the cytosol, resulting in selective cytotoxicity of FAP-expressing cells. In preclinical studies, αFAP-PE38 inhibited tumor growth in mouse models and altered the tumor microenvironment by reducing angiogenic, chemotactic, and immunosuppressive factors.[1][3]

Other names
alphaFAP-PE38alphaFAP-PE-38alphaFAP-PE 38anti-FAP-PE38anti-FAP-PE-38anti-FAP-PE 38FAP-targeting immunotoxin-PE38
02

Targets

EEF2 (Eukaryotic elongation factor 2)FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on αFAP-PE38.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on αFAP-PE38.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call